Veru reports Phase 3 ARTEST data: enobosarm monotherapy shows 12.5% ORR vs 0% control in metastatic breast cancer

VERU INC.

Enobosarm monotherapy achieved 2 PR/16 (12.5%) ORR vs 0 PR/18 for active control in discontinued Phase 3 ARTEST trial.
In patients with ≤3 prior endocrine therapies and ≤1 prior CDK4/6 inhibitor, ORR was 33.3% (2/6) vs 0% control.
Enobosarm was well tolerated with no masculinizing AEs or hematocrit increases.
Trial discontinued to focus on earlier-line ENABLAR-2 Phase 3 study of enobosarm + abemaciclib.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.